# Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.

> **NCT00705588** · PHASE4 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Vardenafil

## Key facts

- **NCT ID:** NCT00705588
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2010-01
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705588, "Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00705588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*